Allovir For Kidney Transplant Patients With Bk Virus
Posted Date: Mar 1, 2021
- Investigator: Ervin Steve Woodle
- Specialties:
- Type of Study: Drug
This multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with low titers of BK viremia. The primary objective is to assess the safety and tolerability of Viralym-M and to test the hypothesis that administration of Viralym-M to kidney transplant recipients with BK viremia will demonstrate superiority in suppressing BK viral load compared with placebo.
Criteria:
Kidney Transplant Recipient With Bk Virus In The Blood
Keywords:
Kidney Transplant, Bk Virus
For More Information:
Amanda Naciff Stahl
558-9965
naciffab@ucmail.uc.edu